Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  American Journal of Physiology. Endocrinology and Metabolism

• Publication date

  2010-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1152/ajpendo.00700.2009PMID 20103744
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus.

  2009cited by this paper
• Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients

  2008cited by this paper
• Reduced Incretin Effect in Type 2 Diabetes

  2007cited by this paper
• Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus

  2007cited by this paper
• Editorial: The role of glucagon in postprandial hyperglycemia--the jury's still out.

  2007cited by this paper
• The physiology of glucagon-like peptide 1.

  2007cited by this paper
• Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects

  2007cited by this paper
• Meal-stimulated glucagon release is associated with postprandial blood glucose level and does not interfere with glycemic control in children and adolescents with new-onset type 1 diabetes.

  2007cited by this paper
• Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans.

  2006cited by this paper
• Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes

  2006cited by this paper
• Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes: documentation of the intraislet insulin hypothesis in humans.

  2005cited by this paper
• Regulation of α-Cell Function by the β-Cell in Isolated Human and Rat Islets Deprived of Glucose: the “Switch-off” Hypothesis

  2004cited by this paper
• Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1.

  2004cited by this paper
• Regulation of alpha-cell function by the beta-cell in isolated human and rat islets deprived of glucose: the "switch-off" hypothesis.

  2004cited by this paper
• Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency.

  2003cited by this paper
• Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

  2003cited by this paper
• No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects†

  2003cited by this paper
• Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.

  2002cited by this paper
• Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects

  2002cited by this paper
• In vivo and in vitro degradation of glucagon-like peptide-2 in humans.

  2000cited by this paper
• Impact of lack of suppression of glucagon on glucose tolerance in humans.

  1999cited by this paper
• Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

  1993cited by this paper
• Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7–36 Amide and Glucagonlike Peptide-1 7–37 in Healthy Subjects Are Indistinguishable

  1993cited by this paper
• Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

  1993cited by this paper
• A General Regression Procedure for Method Transformation. Application of Linear Regression Procedures for Method Comparison Studies in Clinical Chemistry, Part III

  1988cited by this paper
• Glucagon-like peptide-1 7-36: a physiological incretin in man.

  1987cited by this paper
• Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.

  1986cited by this paper
• Glucagon physiology and pathophysiology in the light of new advances

  1985cited by this paper
• Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets

  1985cited by this paper
• Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics.

  1983cited by this paper
• Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin.

  1982cited by this paper
• Control of Pancreatic Glucagon Secretion by Glucose

  1969cited by this paper

• Altered Glucagon Response to Oral Glucose in Individuals at Different Stages of Type 1 Diabetes Development.

  2025cites this paper
• The impact of plasma glucose decline rate on cardiac repolarisation in individuals with type 1 diabetes

  2025cites this paper
• Comparison of an oral mixed meal plus arginine and intravenous glucose, GLP-1 plus arginine to unmask residual islet function in longstanding type 1 diabetes

  2024cites this paper
• The association of fasting and postprandial GIP and glucagon levels with glycemic variability evaluated by flash glucose monitoring system in type 1 diabetes

  2024influential citation
• Abnormal late postprandial glucagon response in type 1 diabetes is a function of differences in stimulated C-peptide concentrations

  2024cites this paper
• Polyester Nanoparticles with Controlled Topography for Peroral Drug Delivery Using Insulin as a Model Protein.

  2024cites this paper
• The effect of small increases in blood glucose on insulin secretion and endogenous glucose production in humans.

  2024cites this paper
• The Importance of Intra-Islet Communication in the Function and Plasticity of the Islets of Langerhans during Health and Diabetes

  2024cites this paper
• The Promise of Adjunct Medications in Improving Type 1 Diabetes Outcomes: Glucagon-Like Peptide Receptor Agonists

  2024cites this paper
• Glucose metabolism, gut-brain hormones, and acromegaly treatment: an explorative single centre descriptive analysis

  2023cites this paper
• Modeling of postprandial glycemic response by consecutive reaction kinetics model for precise glycemic control

  2023cites this paper
• The artificial pancreas: two alternative approaches to achieve a fully closed-loop system with optimal glucose control

  2023cites this paper
• Signs of a Glucose and Insulin-Independent Gut-Bone Axis and Aberrant Bone Homeostasis in Type 1 Diabetes.

  2023cites this paper
• The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD

  2023cites this paper
• Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases

  2023cites this paper
• Metabolic Messengers: glucagon

  2023cites this paper
• Loss of the incretin effect in type 2 diabetes: a systematic review and meta-analysis.

  2022cites this paper
• The Glucagon Receptor Antagonist LY2409021 does not affect gastrointestinal-mediated glucose disposal or the incretin effect in individuals with and without type 2 diabetes.

  2022cites this paper
• C‐peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective

  2022cites this paper
• New Developments in Glucagon Treatment for Hypoglycemia

  2022cites this paper
• Food intake rather than blood glucose levels affects the pharmacokinetic profile of insulin aspart in pigs

  2021cites this paper
• Evidence for glucagon secretion and function within the human gut.

  2021cites this paper
• The Change in Glucagon Following Meal Ingestion Is Associated with Glycemic Control, but Not with Incretin, in People with Diabetes

  2021cites this paper
• The Role of Incretins on Insulin Function and Glucose Homeostasis

  2021influential citation
• Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes.

  2021cites this paper
• KATP channel blockers control glucagon secretion by distinct mechanisms: A direct stimulation of α-cells involving a [Ca2+]c rise and an indirect inhibition mediated by somatostatin

  2021cites this paper
• The enteroendocrine-osseous axis in patients with long-term type 1 diabetes mellitus.

  2021cites this paper
• Mini‐review: Glucagon responses in type 1 diabetes – a matter of complexity

  2021influential citation
• Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post‐meal glucose excursions and glucagon in type 1 diabetes patients

  2020cites this paper
• The role of α-cells in islet function and glucose homeostasis in health and type 2 diabetes.

  2020cites this paper
• Secretion of parathyroid hormone may be coupled to insulin secretion in humans

  2020cites this paper
• Assessment of Islet Alpha- and Beta-Cell Function

  2019cites this paper
• Glucagon Receptor Signaling and Glucagon Resistance

  2019cites this paper
• Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptide

  2019cites this paper
• The incretin system in healthy humans: The role of GIP and GLP-1.

  2019cites this paper
• A gut feeling about glucagon

  2018cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 248 Mechanism-based modelling of clinical and preclinical studies of glucose homeostasis

  2018cites this paper
• Impaired Insulin Action Is Associated With Increased Glucagon Concentrations in Nondiabetic Humans

  2018cites this paper
• Impact of C-Peptide Status on the Response of Glucagon and Endogenous Glucose Production to Induced Hypoglycemia in T1DM

  2018cites this paper
• Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects

  2018cites this paper
• EJE PRIZE 2018: A gut feeling about glucagon.

  2018cites this paper
• Incretin Hormones and Insulin Responses During OGTT in Newly Diagnosed T2DM Patients

  2018cites this paper
• Clinical implications of persistent beta cell function in long duration type 1 diabetes

  2018cites this paper
• Short‐acting glucagon‐like peptide‐1 receptor agonists as add‐on to insulin therapy in type 1 diabetes: A review

  2017cites this paper
• Gastrointestinal and Cardiovascular Effects of Incretin-Based Therapies: Friend or Foe?

  2017cites this paper
• Pleotropic Acute and Chronic Effects of Leptin to Reverse Type 1 Diabetes.

  2017cites this paper
• Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect

  2017cites this paper
• Glucagon in artificial pancreas systems: Potential benefits and safety profile of future chronic use

  2017cites this paper
• Gastrointestinal actions of glucagon‐like peptide‐1‐based therapies: glycaemic control beyond the pancreas

  2016influential citation
• Jejunal administration of glucose enhances acyl ghrelin suppression in obese humans.

  2016cites this paper
• Roles of the Gut in Glucose Homeostasis

  2016cites this paper
• Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease.

  2016cites this paper
• The biology of glucagon and the consequences of hyperglucagonemia.

  2016cites this paper
• Establishment of a Refined Oral Glucose Tolerance Test in Pigs, and Assessment of Insulin, Glucagon and Glucagon-Like Peptide-1 Responses

  2016influential citation
• Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia

  2016cites this paper
• Relationships of gastric emptying with glycaemia, insulin secretion and the incretin effect in health and type 2 diabetes

  2016cites this paper
• Mathematical Model of Glucose-Insulin Metabolism Considering Meal Absorption Rate and Model-based Blood Glucose Control for Prandial State in Type 1 Diabetes

  2016cites this paper
• Chapter 34 – Glucagon and the Glucagon-Like Peptides

  2016cites this paper
• Evidence of Extrapancreatic Glucagon Secretion in Man

  2015influential citation
• Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young.

  2015cites this paper
• Physiological and pathophysiological control of glucagon secretion by pancreatic α-cells

  2015cites this paper
• Influence of gastrointestinal factors on glucose metabolism in patients with cirrhosis

  2015cites this paper
• The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects.

  2014cites this paper
• Alpha cell function in type 1 diabetes

  2014cites this paper
• Glucagon Response to Oral Glucose Challenge in Type 1 Diabetes: Lack of Impact of Euglycemia

  2014cites this paper
• Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist

  2014cites this paper
• The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes

  2014cites this paper
• Glukagonantwort auf orale Glucosebelastung bei Typ-1-Diabetes

  2014cites this paper
• Glucagon and Type 2 Diabetes: the Return of the Alpha Cell

  2014cites this paper
• POUR LE DIPLÔME D'ÉTAT DE DOCTEUR EN MÉDECINE

  2013cites this paper
• Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty

  2013cites this paper
• Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease.

  2013cites this paper
• Effects of Proximal Gut Bypass on Glucose Tolerance and Insulin Sensitivity in Humans

  2013cites this paper
• GLP-1 agonists in type 1 diabetes.

  2013cites this paper
• Metreleptin improves blood glucose in patients with insulin receptor mutations.

  2013cites this paper
• Use of Non-Insulin Therapies for Type 1 Diabetes

  2013influential citation
• Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity

  2012cites this paper
• Enhanced mathematical model of postprandial glycemic excursion in diabetics using rapid-acting insulin

  2012cites this paper
• Decreased active GLP-1 response following large test meal in patients with type 1 diabetes using bolus insulin analogues.

  2011cites this paper
• Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.

  2011cites this paper
• The alpha-cell as target for type 2 diabetes therapy.

  2011cites this paper
• Regulation of glucagon secretion by incretins

  2011cites this paper
• Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes

  2011influential citation
• Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects.

  2010cites this paper
• Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitis.

  2010cites this paper